The potential for aromatase inhibition in breast cancer prevention

Clinical Cancer Research

Volumn 7, Issue , 2001, Pages 4423s-4428s

  Lønning, Per E ^a   Geisler, Jiirgen ^a   Kragh, Lars E ^b   Erikstein, Bjorn ^b   Hagen, Anne ^c   Risberg, Terje ^d   Schlichting, Ellen ^b  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^d Tromsci University Hospital   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ANDROSTENEDIONE; AROMATASE INHIBITOR; EXEMESTANE; FADROZOLE; FORMESTANE; LETROZOLE; PYRIDOGLUTETHIMIDE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

BREAST CANCER; CANCER PREVENTION; CANCER RISK; CLINICAL TRIAL; CONFERENCE PAPER; DRUG STRUCTURE; HIGH RISK PATIENT; HUMAN; METASTASIS; ONCOGENE; POSTMENOPAUSE; PRIORITY JOURNAL; VIRILIZATION;

ANTICARCINOGENIC AGENTS; AROMATASE INHIBITORS; BREAST NEOPLASMS; ENZYME INHIBITORS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MENOPAUSE; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 0035664662     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Efficacy of breast cancer screening by age
2. Polychemotherapy for early breast cancer: An overview of the randomised trials
3. Tamoxifen for early breast cancer: An overview of the randomised trials
4. Molecular portraits of human breast tumours
5. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer
6. Differential responsiveness of human breast cancer cell lines MCF-7 and T47D to growth factors and 17β estradiol
7. Prognostic significance of insulin-like growth factor I receptors in human breast cancer
8. Influence of treatment with tamoxifen and change in tumor burden on the IGF-system in breast cancer patients
9. Influence of tamoxifen on the plasma levels of insulin-like growth factor I and insulin-like growth factor binding protein I in breast cancer patients
10. Microencapsulated octreotide pamoate in advanced gastrointestinal and pancreatic cancer: A Phase I study
11. Safety of the synthetic retinoid fenretinide: Long-term results from a controlled clinical trial for the prevention of contralateral breast cancer
12. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial
13. Prevention of breast cancer with tamoxifen: Preliminary findings from the Italian randomised trial among hysterectomised women
14. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study
15. The effect of raloxifene on risk of breast cancer in postmenopausal women. Results from the MORE randomized trial
16. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial
17. Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation
18. Multiple coronary heart disease risk factors are associated with menopause and influenced by substitutive hormonal therapy in a cohort of French women
19. Prevention and management of osteoporosis. Current trends and future prospects
20. Increased plasma homocysteine after menopause
21. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized crossover-designed study
22. Effect of non-steroidal aromatase inhibitors (AI) on serum lipids profile in patients with breast cancer. Preliminary report
23. Effect of letrozole on the lipid profile in postmenopausal women with breast cancer
24. No adverse impact on serum lipids of the irreversible aromatase inactivator Aromasin (R) (Exemestane (E)) in 1st line treatment of metastatic breast cancer (MBC): Companion study to a European Organization of Research and Treatment of Cancer (Breast Group) trial with Pharmacia & Upjohn
25. Plasma changes in breast cancer patients during endocrine therapy - Lipid measurements and nuclear magnetic resonance (NMR) spectroscopy
26. Effects of treatment with megestrol acetate, aminoglutethimide, or formestane on insulin-like growth factor (IGF) I and II, IGF-binding proteins (IGFBPs), and IGFBP-3 protease status in patients with advanced breast cancer
27. Cancer and thrombosis revisited
28. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: Results of a survival update based on a combined analysis of data from two mature Phase III trials
29. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate
30. Letrozole, a new oral aromatase inhibitor: Randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer
31. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate
32. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a Phase III randomized double-blind trial
33. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial
34. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the tamoxifen or Arimidex randomized group efficacy and tolerability study
35. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a Phase III study of the International Letrozole Breast Cancer Group
36. Efficacy of and tolerance to exemestane (E) versus tamoxifen (T) in 1st line hormone therapy (HT) of postmenopausal metastatic breast cancer (MBC) patients (pts): A European Organisation for the Research and Treatment of Cancer (EORTC Breast Group) Phase II Trial with Pharmacia and Upjohn
37. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews
38. Breast cancer and artificial menopause: A cohort study
39. Menopausebreast cancer risk
40. Serum sex hormone levels after menopause and subsequent breast cancer
41. A prospective study of endogenous estrogens and breast cancer in postmenopausal women
42. A prospective study of endogenous serum hormone concentrations and breast cancer risk in postmenopausal women on the island of Guernsey
43. Serum sex hormone levels are related to breast cancer risk in postmenopausal women
44. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women
45. Profound suppression of plasma estrogens by megestrol acetate in postmenopausal breast cancer patients
46. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer
47. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients
48. In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer
49. Influence of aromatase inhibitors on plasma total homocysteine in postmenopausal breast cancer patients
50. Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer
51. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: A Phase 1 study
52. The influence of CGS 16949A on peripheral aromatisation in breast cancer patients
53. The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patients
54. The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer
55. Combined treatment with 4-hydroxyandrostenedione and aminoglutethimide: Effects on aromatase inhibition and oestrogen suppression
56. The effects of oral 4-hydroxyandrostenedione on peripheral aromatisation in post-menopausal breast cancer patients